Cargando…

Natalizumab: COVID-19 infection: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892751/ http://dx.doi.org/10.1007/s40278-021-91385-8

Ejemplares similares

Natalizumab: COVID-19 infection: 19 case reports
Publicado: (2022)

Alemtuzumab/cladribine/natalizumab: Lymphopenia and COVID-19 infection: case report
Publicado: (2021)

Natalizumab: Pneumonia caused by COVID-19: case report
Publicado: (2020)

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
Publicado: (2021)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Natalizumab: Coronavirus disease-2019 infection: 6 case reports
Publicado: (2022)

Natalizumab: Progressive multifocal leukoencephalopathy: case report
Publicado: (2021)

Natalizumab: Pneumonitis and peripheral blood eosinophilia: case report
Publicado: (2022)

Interferon-beta-1a/natalizumab: Lack of efficacy: case report
Publicado: (2021)

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report
por: Sotgiu, Stefano, et al.
Publicado: (2010)

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
por: Lee, De-Hyung, et al.
Publicado: (2014)

Vaccine-associated measles in a patient treated with natalizumab: a case report
por: Miauton, Alix, et al.
Publicado: (2020)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Pulmonary eosinophilia associated to treatment with natalizumab
por: Curto, Elena, et al.
Publicado: (2016)

A Case of Drug-Induced Liver Injury Secondary to Natalizumab
por: Santoiemma, Phillip P., et al.
Publicado: (2020)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
por: Lo Buono, Viviana, et al.
Publicado: (2022)

Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review
por: Yasuda, Yuichiro, et al.
Publicado: (2019)

Does Natalizumab Induce or Aggravate Psoriasis? A Case Study and Review of the Literature
por: Lambrianides, Sakis, et al.
Publicado: (2018)

Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression
por: Persaud, Stephen P., et al.
Publicado: (2017)

Acute retinal necrosis caused by co-infection with multiple viruses in a natalizumab-treated patient: a case report and brief review of literature
por: Cheraqpour, Kasra, et al.
Publicado: (2021)

Natalizumab-induced thrombocytopenia: A case report
por: Azimi, Amirreza, et al.
Publicado: (2022)

Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series
por: Chisari, Clara G., et al.
Publicado: (2021)

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy
por: Godano, Elisabetta, et al.
Publicado: (2021)

Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report
por: De Masi, Roberto, et al.
Publicado: (2022)

Non-Hodgkin Lymphoma of the Stomach in a Patient Treated with Natalizumab
por: Law, Jennie Y, et al.
Publicado: (2015)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
por: Herold, Tina Rike, et al.
Publicado: (2012)

Immune Reconstitution Inflammatory Syndrome Mimicking Progressive Multifocal Leucoencephalopathy in a Multiple Sclerosis Patient Treated With Natalizumab: A Case Report and Review of the Literature
por: Evangelopoulos, Maria-Eleptheria, et al.
Publicado: (2015)

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report
por: Patti, Francesco, et al.
Publicado: (2015)

Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber’s optic neuropathy and multiple sclerosis – a case report
por: Holmøy, Trygve, et al.
Publicado: (2016)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”
por: Mansoor, Salman, et al.
Publicado: (2021)

Treatment with natalizumab during the Covid-19 pandemic in multiple sclerosis patients
por: Díaz-Díaz, Judit, et al.
Publicado: (2021)

Antineoplastics: Covid-19 infection: 19 case reports
Publicado: (2021)

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
por: Borriello, Giovanna, et al.
Publicado: (2020)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Etanercept: COVID-19 infection: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2srcpsrlhbkgl13m8bcodl33m6